Source: Annual Congress 2004 - Pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Doyen, P. Bulpa, J. Jamart, E. Installé, P. Evrard (Yvoir, Belgium). Intrapulmonary shunt effect induces by nicardipine but not by urapidil in pulmonary hypertension. Eur Respir J 2004; 24: Suppl. 48, 1299

Member's Comments

No comment yet.

Related content which might interest you: Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Effects of suramin on cardiopulmonary capacity and pulmonary venous contraction in pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 339-343 Year: 2002 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence Source: Eur Respir J 2009; 34: 7-9 Year: 2009 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy Year: 2005 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009 Inhaled iloprost improves hemodynamics at exercise in primary and secondary precapillary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension Source: Eur Respir J 2001; 17: 14-19 Year: 2001